Management of acute exacerbations of chronic pulmonary obstructive disease

Descripción del Articulo

Chronic obstructive lung disease (COPD) is an important cause of death in industrialized countries (it is the 4th cause of death in the U.S.). This condition is also prevalent in developing countries, in some its frequency may be higher, and it is an important cause of hospitalizations and consultat...

Descripción completa

Detalles Bibliográficos
Autor: Gayoso Cervantes, Oscar
Formato: artículo
Fecha de Publicación:2009
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:ojs.pkp.sfu.ca:article/1537
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/1537
Nivel de acceso:acceso abierto
Materia:Chronic airflow obstruction
Chronic obstructive airway disease (COAD)
Chronic obstructive pulmonary disease (COPD)
id REVCMP_96a6e1cde1164b37ebfcf7ac3f817991
oai_identifier_str oai:ojs.pkp.sfu.ca:article/1537
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
dc.title.none.fl_str_mv Management of acute exacerbations of chronic pulmonary obstructive disease
Manejo de la exacerbación aguda en la enfermedad pulmonar obstructiva crónica
title Management of acute exacerbations of chronic pulmonary obstructive disease
spellingShingle Management of acute exacerbations of chronic pulmonary obstructive disease
Gayoso Cervantes, Oscar
Chronic airflow obstruction
Chronic obstructive airway disease (COAD)
Chronic obstructive pulmonary disease (COPD)
title_short Management of acute exacerbations of chronic pulmonary obstructive disease
title_full Management of acute exacerbations of chronic pulmonary obstructive disease
title_fullStr Management of acute exacerbations of chronic pulmonary obstructive disease
title_full_unstemmed Management of acute exacerbations of chronic pulmonary obstructive disease
title_sort Management of acute exacerbations of chronic pulmonary obstructive disease
dc.creator.none.fl_str_mv Gayoso Cervantes, Oscar
author Gayoso Cervantes, Oscar
author_facet Gayoso Cervantes, Oscar
author_role author
dc.subject.none.fl_str_mv Chronic airflow obstruction
Chronic obstructive airway disease (COAD)
Chronic obstructive pulmonary disease (COPD)
topic Chronic airflow obstruction
Chronic obstructive airway disease (COAD)
Chronic obstructive pulmonary disease (COPD)
description Chronic obstructive lung disease (COPD) is an important cause of death in industrialized countries (it is the 4th cause of death in the U.S.). This condition is also prevalent in developing countries, in some its frequency may be higher, and it is an important cause of hospitalizations and consultations because of acute exacerbations. The Anthonisen definition is the most widely and accepted instrument for diagnosing COPD exacerbations, pointing out at the presence of one or more of the following: increased sputum volume, change of color of the sputum, and worsening dyspnea. Patients with COPD may develop one to three acute exacerbation episodes per year. The number of these episodes is an important marker for the severity of COPD, since it determines quality of life and the mortality risk. Three to sixteen per cent of affected patients may require hospitalization (this rate may be higher in more severe cases). In-hospital mortality may reach 10% in severe COPD cases, and it becomes increased if the patient is admitted to an intensive care unit. The etiology of acute exacerbations of COPD is mainly because of infections (up to 80%), but other conditions may also account for such exacerbations, such as pulmonary embolism, pneumothorax, heart failure, thoracic trauma (including rib fracture), and extrapulmonary infections, being considered as triggering factors, and they may also coexist. Differently from asthma crisis, it is important to have a chest X-ray film taken and arterial blood gases determinations in every patient presenting to the emergency department with an acute exacerbation of COPD. Up to 20% of patients may present with elevated PCO2. When administering oxygen, it is preferable to use a Venturi mask with an oxygen concentration able to maintain hemoglobin saturation around 90% (86-92%). The first choice therapy in these cases is the use of a bronchodilator agent. The best option is to use a short acting beta-agonist or an anticholinergic drug, and these drugs may be combined if the patient does not improve his/her condition. The choice of drugs to be use will depend on the underlying conditions of the patient and on the potential side effects. Nebulizations are quite useful, and the use of fixed-dose pressurized inhalers is not precluded; in case of using these devices, a spacer must be used. The use of systemic steroids is controversial. These compounds must not be used for long time periods. If used, therapy should not last for more than 14 days. Antimicrobials are quite useful. Generally speaking, microorganisms involved include enteric Gram-negative bacteria, which are more drug-resistant as long as the obstruction becomes worse (lower FEV1 values) with a worsening clinical condition. It is important to rule out the presence of active tuberculosis, especially if fluoroquinolone compound active against M. tuberculosis are to be used. The choice for antibacterial therapy will depend on the severity of the condition as well as on the presence of risk factors for the development of resistance to antimicrobial agents. Physiotherapy and mucolytic agents have a limited role in an acute setting, but they are important when dealing with COPD management in the long term. A great breakthrough in the management of acute exacerbations of COPD is non-invasive ventilation, which is a safe and effective approach for treating patients with acute hypercarbia. Non-invasive ventilation may fail in up to 30% of all cases, depending on the degree of academia and CO2 levels on admission. Non-invasive ventilation allows the diaphragm muscle to relax and overcome the critical situation preventing exhaustion. Non-invasive ventilation has been proven to reduce the number of intubations and mortality in patients with acute exacerbations of COPD.
publishDate 2009
dc.date.none.fl_str_mv 2009-12-31
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1537
url https://amp.cmp.org.pe/index.php/AMP/article/view/1537
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1537/969
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol 26 No 4 (2009); 251 - 258
ACTA MEDICA PERUANA; Vol. 26 Núm. 4 (2009); 251 - 258
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1816075108240850944
spelling Management of acute exacerbations of chronic pulmonary obstructive diseaseManejo de la exacerbación aguda en la enfermedad pulmonar obstructiva crónicaGayoso Cervantes, OscarChronic airflow obstructionChronic obstructive airway disease (COAD)Chronic obstructive pulmonary disease (COPD)Chronic obstructive lung disease (COPD) is an important cause of death in industrialized countries (it is the 4th cause of death in the U.S.). This condition is also prevalent in developing countries, in some its frequency may be higher, and it is an important cause of hospitalizations and consultations because of acute exacerbations. The Anthonisen definition is the most widely and accepted instrument for diagnosing COPD exacerbations, pointing out at the presence of one or more of the following: increased sputum volume, change of color of the sputum, and worsening dyspnea. Patients with COPD may develop one to three acute exacerbation episodes per year. The number of these episodes is an important marker for the severity of COPD, since it determines quality of life and the mortality risk. Three to sixteen per cent of affected patients may require hospitalization (this rate may be higher in more severe cases). In-hospital mortality may reach 10% in severe COPD cases, and it becomes increased if the patient is admitted to an intensive care unit. The etiology of acute exacerbations of COPD is mainly because of infections (up to 80%), but other conditions may also account for such exacerbations, such as pulmonary embolism, pneumothorax, heart failure, thoracic trauma (including rib fracture), and extrapulmonary infections, being considered as triggering factors, and they may also coexist. Differently from asthma crisis, it is important to have a chest X-ray film taken and arterial blood gases determinations in every patient presenting to the emergency department with an acute exacerbation of COPD. Up to 20% of patients may present with elevated PCO2. When administering oxygen, it is preferable to use a Venturi mask with an oxygen concentration able to maintain hemoglobin saturation around 90% (86-92%). The first choice therapy in these cases is the use of a bronchodilator agent. The best option is to use a short acting beta-agonist or an anticholinergic drug, and these drugs may be combined if the patient does not improve his/her condition. The choice of drugs to be use will depend on the underlying conditions of the patient and on the potential side effects. Nebulizations are quite useful, and the use of fixed-dose pressurized inhalers is not precluded; in case of using these devices, a spacer must be used. The use of systemic steroids is controversial. These compounds must not be used for long time periods. If used, therapy should not last for more than 14 days. Antimicrobials are quite useful. Generally speaking, microorganisms involved include enteric Gram-negative bacteria, which are more drug-resistant as long as the obstruction becomes worse (lower FEV1 values) with a worsening clinical condition. It is important to rule out the presence of active tuberculosis, especially if fluoroquinolone compound active against M. tuberculosis are to be used. The choice for antibacterial therapy will depend on the severity of the condition as well as on the presence of risk factors for the development of resistance to antimicrobial agents. Physiotherapy and mucolytic agents have a limited role in an acute setting, but they are important when dealing with COPD management in the long term. A great breakthrough in the management of acute exacerbations of COPD is non-invasive ventilation, which is a safe and effective approach for treating patients with acute hypercarbia. Non-invasive ventilation may fail in up to 30% of all cases, depending on the degree of academia and CO2 levels on admission. Non-invasive ventilation allows the diaphragm muscle to relax and overcome the critical situation preventing exhaustion. Non-invasive ventilation has been proven to reduce the number of intubations and mortality in patients with acute exacerbations of COPD.La enfermedad pulmonar obstructiva crónica (EPOC), es una causa importante de muerte en países desarrollados (ocupa el cuarto lugar en EUA). Se ha determinado que es tan o más frecuente en los países en desarrollo, es causa de muchas hospitalizaciones y consultas por exacerbación aguda de la enfermedad (EABC). La definición de Anthonisen es la más usada y aceptada, pues señala la presencia de uno o más de los siguientes criterios: incremento en el volumen de la expectoración, cambio de color (purulencia) en el esputo y empeoramiento de la disnea. El paciente con EPOC puede presentar de una a tres exacerbaciones agudas por año. El número de EABC es un marcador importante de severidad de la condición, pues determina la calidad de vida y mortalidad del paciente. Del 3 a 16% requiere hospitalizarse (más en casos severos). La mortalidad hospitalaria puede llegar a 10% en casos de EPOC severos y mayor si el paciente ingresa a una Unidad de Cuidado Intensivo. La etiología de la EABC es mayoritariamente infecciosa, (hasta el 80%), otras condiciones pueden explicarla, como la embolia pulmonar, neumo¬tórax, insuficiencia cardiaca, fracturas en la caja torácica e infecciones no pulmonares, las cuales se consideran como “gatillos” y pueden coexistir más de uno por vez. A diferencia de la crisis asmática es importante que se realice una radiografía de tórax y una gasometría arterial, en todos los pacientes que acuden a la emergencia. Hasta el 20% de pacientes pueden presentar elevación del PCO2. al administrarles oxígeno, se recomienda usar de preferencia una máscara de venturi con la concentración necesaria para llevar la saturación de hemoglobina alrededor de 90% (86-92%). El uso de un broncodilatador es la elección en estos casos. Lo ideal es administrar un beta agonista de corta acción o un anticolinérgico, y si el paciente no mejora se pueden combinar. La elección va a depender de las condiciones existentes en el paciente y los efectos colaterales potenciales. La nebulización es de gran utilidad, pero no está excluido el uso de inhaladores presurizados en dosis fijas; en caso de elegirlo úselo con un espaciador. El uso de esteroides sistémicos es controversial, no deben usarlo por períodos largos. No superar los 14 días. Los antibióticos son de gran utilidad. En general la fauna microbiológica varía hacia gérmenes Entéricos Gram negativos y mayor resistencia con el agravamiento de la obstrucción (menor VEF1) y mayor compromiso clínico del paciente. Es importante realizar descarte para tuberculosis activa especialmente si va a usar fluoroquinolonas con gran actividad sobre el micobacterium. La elección del antibiótico depende de la severidad y de la presencia de factores de riesgo de resistencia antibiótica. El rol de la fisioterapia y de los mucolíticos es limitado en el momento agudo, pero importante para el manejo crónico del EPOC. Un gran avance en el manejo de esta condición es la ventilación no invasiva que permite tratar de manera segura y efectiva a los pacientes con hipercarbia aguda. Fallará en 30 % de casos, los cuales pueden ser detectados por el grado de acidemia y gran elevación de CO2 al ingreso. La VNI permite descansar al músculo diafragma y superar la crisis evitando el agotamiento. La VNI ha demostrado que disminuye el número de intubaciones y la mortalidad en los pacientes con EABC.Colegio Médico del Perú2009-12-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/1537ACTA MEDICA PERUANA; Vol 26 No 4 (2009); 251 - 258ACTA MEDICA PERUANA; Vol. 26 Núm. 4 (2009); 251 - 2581728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1537/969Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:ojs.pkp.sfu.ca:article/15372023-07-06T06:01:15Z
score 13.7211075
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).